Prostate Cancer Resource Page


Prostate Cancer Resource Page

Prostate cancer is the second most common cancer in men worldwide, and experts say that one in eight men will be diagnosed with the disease within their lifetime. However, early detection and vigilant management has proven to be effective, and the American Cancer Society estimates a 98% five-year relative survival rate for those diagnosed with prostate cancer.

Imaging has an increasingly significant role to play as a sensitive and specific non-invasive exam for prostate cancer detection, staging, and monitoring. Imaging allows early detection and complex monitoring capabilities, all without the complications that arise with traditional systematic biopsies or the low specificity of PSA (prostate-specific antigen) levels.

At Keosys, we have multiple resources exploring the treatment and management of prostate cancer. In this collection, you’ll find innovative treatment insights, trends/predictions from industry experts, and more.

Prostate Cancer Resource Library

eBook: Prostate Cancer and Imaging in Clinical Trials

Prostate cancer is a complex disease, so we’ve broken down the basics of detection, management, and treatment in this 17-page eBook. Download this free resource to learn more about how imaging is revolutionizing the treatment of the cancer by offering a non-invasive way to detect tumor response and more.

Infographic: Imaging Assessments

Prostate Cancer Working Group 3 (PCWG3) is an international working group of experts in prostate cancer who provided a framework for the assessment of subjects with castration-resistant prostate cancer enrolled in clinical trials. View our infographic with a summary of PCWG3’s guidance and key points for the assessment of imaging from the committee’s updated recommendations.

Interview: A Clinical R&D Expert Talks About the Future of Radiopharmaceuticals

With a background in clinical research and development, UK-trained physician Dan Stevens currently serves as Vice President for Clinical Development and Medical at Blue Earth Therapeutics, a company currently working on radiopharmaceutical therapies for the treatment of prostate cancer. We spoke with Dan about the radiopharmaceutical field and his predictions for future radiopharmaceutical therapies in oncology. Read our conversation excerpts now.

Did you find these resources helpful? For the latest news and insights about medical imaging, clinical trials, and Keosys, subscribe to our monthly newsletter.

More Posts

New call-to-action